British Oxfam Urges Thailand Not To Scrap Compulsory-Licensing Policy
This article was originally published in PharmAsia News
Executive Summary
Oxfam, an England-based non-government organization, called on the new government in Thailand to maintain the compulsory-licensing policy of the previous government as a way to keep the prices of life-saving drugs affordable. The group's HIV/AIDS director expressed his concern based on the new government's decision to review the policy. The director said the actions of the previous military-led administration made key AIDS drugs, Bristol-Myers Squibb's Stocrin (efavirenx), sold in the United States as Sustiva, and Abbott Laboratories' version Kaletra (lopinavir, ritonavir), more accessible to more than 120,000 patients. (Click here for more
|
Oxfam, an England-based non-government organization, called on the new government in Thailand to maintain the compulsory-licensing policy of the previous government as a way to keep the prices of life-saving drugs affordable. The group's HIV/AIDS director expressed his concern based on the new government's decision to review the policy. The director said the actions of the previous military-led administration made key AIDS drugs, Bristol-Myers Squibb's Stocrin (efavirenx), sold in the United States as Sustiva, and Abbott Laboratories' version Kaletra (lopinavir, ritonavir), more accessible to more than 120,000 patients. (Click here for more ) "Oxfam Urges Thailand Not To Scrap Compulsory Licensing" - Thai News Agency (2/19/08) |